Loading
AL
Achieve Life Sciences, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 19 Mar 2025.
Achieve Life Sciences, Inc.: what insiders have been doing
This page follows insider dealings at Achieve Life Sciences, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. From 18 October 2025 to 18 October 2026, the disclosure feed for Achieve Life Sciences, Inc. logged 2 filings by 2 insiders.
No insider bought on the market over the period, while 1 insider filed 1 sale totalling €151k. At €151k, the sale published on 21 August 2026 by Stewart Richard Alistair is the largest of the period (0.021% of market cap).
With 2 filings in twelve months, the company is quieter than the median of 19 filings across the 5,816 companies we follow on the same exchange. Looking back to 2021, when coverage begins, insiders filed 7 purchases and 1 sale.
Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
47
Thresholds
n/a
Buy Volume
€197,470
7 ops. · all time
Sell Volume
€151,265
1 ops. · all time
Who traded when
BuySaleRichard Alistair Stewart1 buy1 sale
Mark K. Oki1 buy
Since the insiders bought
- +45.5%Entry US$2.75 · Close at T+365 US$4.00
- +45.5%Entry US$2.75 · Close at T+365 US$4.00
- -28.3%Entry US$4.38 · Close at T+365 US$3.14
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Achieve Life Sciences, Inc. Strong Buy (bullish), based on 13 analysts. Average price target: US$14.15.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$6.97
Analyst consensus
13 analystsStrong buy
US$9.00Target US$14.15(+103%)US$21.00
Income statement
EBITDA-US$53.6M
Net income-US$54.6M0.0% margin
Valuation
PER (forward)-10.7x
P/Book32.3x
Beta2.31
Balance sheet & cash
Market capUS$718.6M
Total debtUS$15M
Free Cash Flow-US$49.5M
Debt / Equity140%
Profitability & ownership
ROE-845.0%
ROA-29.2%
% insiders0.9%
% institutions82.1%
Last declaration on 21 August 2026
Declarations47 total
20,626 shares@ US$8.4930.021% mcap38.1% of flowCommon StockSEC:0001193125-26-361182:0
20,626 shares@ US$7.520.019% mcap33.8% of flowCommonSEC144:0001949846-26-000528
168,000 shares0Common StockSEC:0001193125-25-211404:0
297,500 shares0Common StockSEC:0001193125-25-211392:0
455,000 shares0Common StockSEC:0000950170-25-113591:0
110,000 shares0Common StockSEC:0000950170-25-113588:0
69,000 shares0Common StockSEC:0000950170-25-113581:0
10,000 shares@ US$2.85986.6% of flowCommon StockSEC:0000950170-25-042060:0
Canonical exit: 15 Jun 2025 (T+90)
10,000 shares@ US$2.8887100.0% of flowCommon StockSEC:0000950170-25-042074:0
Canonical exit: 15 Jun 2025 (T+90)
2,660 shares@ US$3.6715.6% of flowCommon StockSEC:0000950170-24-099082:0
5,000 shares@ US$3.678.6% of flowCommon StockSEC:0000950170-24-099074:0
16,250 shares0Common StockSEC:0000950170-24-046974:0
25,000 shares0Common StockSEC:0000950170-24-046936:0
22,500 shares0Common StockSEC:0000950170-24-046962:0
6,088 shares@ US$4.5113.3% of flowCommon StockSEC:0000950170-24-046936:1
10,125 shares@ US$4.5110.8% of flowCommon StockSEC:0000950170-24-046962:1
3,957 shares@ US$4.5129.4% of flowCommon StockSEC:0000950170-24-046974:1
10,000 shares@ US$4.58521.8% of flowCommon StockSEC:0000950170-24-027243:0
Canonical exit: 2 Jun 2024 (T+90)
10,000 shares@ US$4.58510.7% of flowCommon StockSEC:0000950170-24-027261:0
Canonical exit: 2 Jun 2024 (T+90)
5,000 shares@ US$5.5013.2% of flowCommon StockSEC:0001209191-23-033392:0
Canonical exit: 28 Aug 2023 (T+90)
5,000 shares0Common StockSEC:0001209191-23-026318:0
25 of 47 declarations
About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. (ticker: ACHV) is a U.S.-based biopharmaceutical company listed on the NASDAQ market in the United States. The company operates with a dual footprint in Bothell/Seattle, Washington, and Vancouver, British Columbia, but its corporate identity and capital-market access are firmly anchored in the United States. Achieve is a specialty pharmaceutical company focused on a single therapeutic theme: nicotine dependence. Its lead asset is cytisinicline, an investigational therapy intended for smoking cessation and, potentially, vaping cessation as well. ([sec.gov](https://www.sec.gov/Archives/edgar/data/949858/000119312526159189/achv-20260415.htm?utm_source=openai))
Historically, Achieve was built around clinical research aimed at addressing nicotine addiction, and its current strategy remains highly concentrated rather than diversified. The company describes itself as a late-stage specialty pharmaceutical business, which is important for investors because it signals a development model driven by clinical milestones, regulatory events, and eventual commercialization rather than a broad portfolio of marketed products. In practical terms, ACHV is essentially a single-asset story, with shareholder value heavily dependent on cytisinicline’s clinical, regulatory, and launch execution. ([ir.achievelifesciences.com](https://ir.achievelifesciences.com/news-events/press-releases/detail/257/achieve-life-sciences-announces-up-to-354-million-private-placement?utm_source=openai))
Read moreShow less
From a competitive standpoint, Achieve targets a large public-health market that remains underserved: tobacco cessation and the broader treatment of nicotine dependence. The company positions cytisinicline as a potential new option in a therapeutic area that has seen limited innovation for many years. Its core activities therefore include drug development, manufacturing readiness, regulatory preparation, and commercialization planning. In April 2026, Achieve announced completion of the technology transfer for manufacturing to U.S.-based Adare Pharma Solutions, an operational step that strengthens its readiness for a possible launch in the United States. ([ir.achievelifesciences.com](https://ir.achievelifesciences.com/news-events/press-releases/detail/256/achieve-life-sciences-announces-operational-progress-including-completion-of-technology-transfer-to-adare-pharma-solutions?utm_source=openai))
Geographically, the company’s operating base is primarily North American, with U.S. headquarters and a Vancouver presence, while management has described the commercialization opportunity as global. For investors, ACHV represents a classic small-cap biotech catalyst profile: the upside case depends on regulatory progress rather than on current product revenue diversification. A key near-term milestone is the FDA PDUFA target action date of June 20, 2026 for cytisinicline in smoking cessation. Management has also highlighted the potentially larger vaping-cessation opportunity, and the company recently announced a private placement of up to $354 million, the appointment of Andrew D. Goldberg as CEO, and additional board and commercial leadership additions in May 2026. ([ir.achievelifesciences.com](https://ir.achievelifesciences.com/news-events/press-releases/detail/247/achieve-life-sciences-reports-third-quarter-2025-financial-results-provides-updates-on-cytisinicline-program?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
